[go: up one dir, main page]

WO2003013490A1 - Preparations nutritives et therapeutiques ayant une activite antioxydante - Google Patents

Preparations nutritives et therapeutiques ayant une activite antioxydante Download PDF

Info

Publication number
WO2003013490A1
WO2003013490A1 PCT/EP2002/007335 EP0207335W WO03013490A1 WO 2003013490 A1 WO2003013490 A1 WO 2003013490A1 EP 0207335 W EP0207335 W EP 0207335W WO 03013490 A1 WO03013490 A1 WO 03013490A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
acid
adenine
nicotine
polycosanols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/007335
Other languages
English (en)
Inventor
Elvira Pistolesi
Benvenuto Cestaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunza Di Pistolesi Elvira & C Sas
Original Assignee
Hunza Di Pistolesi Elvira & C Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunza Di Pistolesi Elvira & C Sas filed Critical Hunza Di Pistolesi Elvira & C Sas
Publication of WO2003013490A1 publication Critical patent/WO2003013490A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • polycosanolic acids examples include octacosanolic acid (montanic acid), triacosanolic, tetracosanolic, hexacosanolic acids, and the like.
  • Preferred sources of these polycosanolic acids are suitably purified wax fractions of maize, wheat, rice, citrus fruits, sugar cane, sea animals fats, and the like.
  • these fatty polycosanolic acids can easily be obtained by chemical oxidation of the alcohol group of the corresponding polycosanols according to conventional oxidation procedures known in literature, and the like.
  • Ribose is present in such amounts as to provide a daily dosage ranging from 0.1 to 500 mg, preferably from 0.5 to 20 mg for kg.
  • Pyrophosphoric acid or the salts thereof are present in such amounts as to provide a daily dosage ranging from 0.1 to 500 mg, preferably from 0.5 to 20 mg per kg body weight of the treated subject.
  • compositions of the invention can further contain other conventional components, such as vitamins, oligoelements, mineral salts, phytosterols, terpenes, essential oils, bioflavones, extracts of medicinal herbs, amino acids, peptides and the like.
  • compositions of the invention can be added to flours for the preparation of bakery products (bread, pasta, cracker, biscuits, etc.); to fruit juices, soft drinks or other beverages; to milk and derivatives thereof (yogurt, puddings, ricotta, cheese, etc.).
  • said powders can be used for galenic formulations, such as sugar-coated pills, sachets, effervescent tablets, chewing gums, ampoules, etc.
  • the compositions of the invention may also be added to topical formulations for use in cosmetics. Examples of cosmetic formulations which can contain the compositions of the invention are creams, milks, lotions, emulsions, ointments, gels, foams, sprays and the like.
  • deambulation activity which are an indication of the alert state and well-being of the rats.
  • the 4 th group was treated with a mixture of polycosanols (50%) and polycosanolic acids (50%) (PLC); the animals received for 40 days the same diet as the controls, added with 0.1% of a mixture of polycosanols and polycosanolic acids.
  • PLC polycosanolic acids
  • the animals received for 40 days the same diet as the controls, added with 0.75% of a mixture containing 0.25% of NADH 2 and 0.50% of nicotinamide + adenosine + ribose + pyrophosphates (as reported for the 2 nd group).
  • the 7 th group was treated with an M + N + PLC mixture (TERNARY MIX); the animals received for 40 days the same diet as the controls, added with 0.85% of a mixture containing 0.25% of NADH 2 , 0.50% of nicotinamide + adenosine + ribose + pyrophosphates (as reported for the 2 nd group) and 0.1% of a mixture of polycosanols and polycosanolic acids (as reported for the 4 th group).
  • Clinical trials were carried out on different groups of patients both healthy and suffering from one or more of the many aging-related dysmetabolic disorders (atherosclerosis; obesity and overweight; hypercholesterolemia and/or hypertriglyceridemia; hypertension; diabetes; cerebral-degenerative diseases such as Alzheimer, Parkinson, senile dementia, loss of memory and the like; stress and/or depression; menopausal syndromes; prostate hypertrophy; osteoporosis; aging of the skin; panniculopathies (cellulite); alopecia). Patients were subjected to dietotherapic treatment with the mixtures reported in Example 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des préparations pharmaceutiques et diététiques ou des produits alimentaires pour humains ou animaux, capables de prévenir le processus de vieillissement et faisant office d'adjuvants dans le traitement de troubles associés.
PCT/EP2002/007335 2001-08-03 2002-07-03 Preparations nutritives et therapeutiques ayant une activite antioxydante Ceased WO2003013490A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI01A001707 2001-08-03
IT2001MI001707A ITMI20011707A1 (it) 2001-08-03 2001-08-03 Preparazioni nutrizionali e terapeutiche dotate di attivita' antiossidante ed in grado di controllare sia i danni da perossidazione del dna

Publications (1)

Publication Number Publication Date
WO2003013490A1 true WO2003013490A1 (fr) 2003-02-20

Family

ID=11448230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007335 Ceased WO2003013490A1 (fr) 2001-08-03 2002-07-03 Preparations nutritives et therapeutiques ayant une activite antioxydante

Country Status (2)

Country Link
IT (1) ITMI20011707A1 (fr)
WO (1) WO2003013490A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067902A1 (fr) * 2004-01-20 2005-07-28 Panacea Biotec Ltd., Nouvelles compositions comprenant des alcools primaires superieurs et de l'acide nicotinique et procede de preparation correspondant
EP1839652A1 (fr) * 2006-03-21 2007-10-03 Clariant International Ltd. Produit destiné à l'influence positive de la maladie d'Alzheimer et/ou destiné à la prophylaxie de la maladie d'Alzheimer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
US5973224A (en) * 1996-04-03 1999-10-26 Fuchs; Norbert Dietetical combination preparations
EP1161884A1 (fr) * 2000-06-09 2001-12-12 World Pharma Tech Ltd. Supplément alimentaire proénergétique basé sur NADH, Octacosanol et Vitamine E

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
US5973224A (en) * 1996-04-03 1999-10-26 Fuchs; Norbert Dietetical combination preparations
EP1161884A1 (fr) * 2000-06-09 2001-12-12 World Pharma Tech Ltd. Supplément alimentaire proénergétique basé sur NADH, Octacosanol et Vitamine E

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BREIER S ET AL: "Oberflächenlipide von Plücksalatsorten unter besonderer Berücksichtigung der Alkane und primären Alkohole.", GARTENBAUWISSENSCHAFT 1987 INST. FÜR OBST-, GEMÜSE- UND WEINBAU, UNIV. HOHENHEIM, HOHENHEIM, STUTTGART, FEDERAL REPUBLIC OF GERMANY, vol. 52, no. 3, pages 97 - 102, XP001107116 *
DIMITRIOS B ET AL: "Tetracosanol and hexacosanol content of Greek olive oils.", GRASAS Y ACEITES 1983 LAB. OF ORGANIC CHEM. TECH., UNIV. OF THESSALONIKI, THESSALONIKI, GREECE, vol. 34, no. 6, pages 402 - 404, XP001118813 *
EISENBRAND G, SCHREIER P (HRSG.): "Römpp Lexikon Lebensmittelchemie", 1995, GEORG THIEME VERLAG, STUTTGART, XP002218909 *
ITO S ET AL: "WAX LIPID IN RICE BRAN", NIPPON NOGEIKAGAKU KAISHI, vol. 55, no. 3, 1981, pages 247 - 253, XP001118715, ISSN: 0002-1407 *
KAWANISHI K ET AL: "FREE PRIMARY ALCOHOLS IN OILS AND WAXES FROM GERMS KERNELS AND OTHER COMPONENTS OF NUTS SEEDS FRUITS AND CEREALS", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, vol. 68, no. 11, 1991, pages 869 - 872, XP001118824, ISSN: 0003-021X *
KRULICK S ET AL: "HEXACOSANOL AND OCTACOSANOL METABOLITES OF DISRUPTED POTATO TUBER TISSUE", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 27, no. 1, 1979, EN, pages 212 - 213, XP001118736, ISSN: 0021-8561 *
MORICE I M ET AL: "Composition of the surface waxes of apple fruits and changes during storage.", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE 1973 FOOD CHEM. DIV., DEPT. OF SCI. AND IND. RES., WELLINGTON, NEW ZEALAND, vol. 24, no. 11, pages 1331 - 1339, XP001118092 *
OHNISHI M ET AL: "COMPOSITION AND MOLECULAR SPECIES OF WAXY LIPIDS IN WHEAT GRAIN", CEREAL CHEMISTRY, vol. 63, no. 3, 1986, pages 193 - 196, XP001118815, ISSN: 0009-0352 *
TULLOCH A P ET AL: "LEAF WAX OF DURUM WHEAT-M", PHYTOCHEMISTRY (OXFORD), vol. 10, no. 4, 1971, pages 871 - 876, XP001118093, ISSN: 0031-9422 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067902A1 (fr) * 2004-01-20 2005-07-28 Panacea Biotec Ltd., Nouvelles compositions comprenant des alcools primaires superieurs et de l'acide nicotinique et procede de preparation correspondant
AU2005205164B2 (en) * 2004-01-20 2008-04-24 Panacea Biotec Ltd. Novel compositions comprising higher primary alcohols and nicotinic acid and process of preparation thereof
EP1839652A1 (fr) * 2006-03-21 2007-10-03 Clariant International Ltd. Produit destiné à l'influence positive de la maladie d'Alzheimer et/ou destiné à la prophylaxie de la maladie d'Alzheimer

Also Published As

Publication number Publication date
ITMI20011707A1 (it) 2003-02-03
ITMI20011707A0 (it) 2001-08-03

Similar Documents

Publication Publication Date Title
CN101516386B (zh) 包含玫瑰果和其它活性剂的用于治疗炎性病症的组合物
EP1439831B1 (fr) Preparation nutraceutique ayant un effet de nutrition d'appoint et d'amelioration de nutrition
KR101780079B1 (ko) 모발 관리용 스테비아 추출물 또는 스테비올
JP4658348B2 (ja) コラーゲン産生促進剤、コラゲナーゼ阻害剤、線維芽細胞増殖作用剤、エラスターゼ阻害剤、エストロゲン様作用剤、並びに皮膚化粧料
KR101661793B1 (ko) 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품
WO2005072684A1 (fr) Procédé de production de l'extrait de maca
KR101889793B1 (ko) 수산동물 발효물을 포함하는 탈모 방지 및 육모 촉진을 위한 조성물
JP2002003393A (ja) 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料
US20090269424A1 (en) Peripheral blood flow-improving composition
JP5027361B2 (ja) ヒアルロン酸産生促進剤
CN101945651A (zh) 包含羟基酪醇和软骨素的组合物及其用于治疗、辅助治疗或预防炎性病症的用途
JP2011055837A (ja) 美容用飲食品
WO2003013490A1 (fr) Preparations nutritives et therapeutiques ayant une activite antioxydante
JP6964290B2 (ja) Ａｔｐ産生促進用剤
JP2004161678A (ja) 抗炎症剤及びサイクリックａｍｐホスホジエステラーゼ阻害剤
KR101903905B1 (ko) 핑클루비 (Sedeveria Pink Ruby) 추출물을 유효성분으로 포함하는, 항암 또는 항산화용 조성물
JP6105186B2 (ja) 膵リパーゼ阻害剤
KR20240040487A (ko) 플라티코딘 d 및 폴리갈락신 d의 함량이 증대된 도라지 추출법
KR20200043476A (ko) 간보호, 숙취해소, 항산화 및 항염증 효능을 갖는 펩티드
JP4672304B2 (ja) 脂肪分解促進剤
JP2013166719A (ja) Ａｍｐｋ活性化剤
JP4542765B2 (ja) 酵素阻害剤
KR20180102415A (ko) 비자 열매 추출물 또는 이의 분획물을 포함하는 항산화 또는 항염증 조성물
JP4224593B2 (ja) ワサビを有効成分とする脂肪蓄積抑制用組成物
WO2008023425A1 (fr) Composition pour l'amélioration de l'état de la peau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP